Moderna's combination vaccine, mRNA-1083, has demonstrated a strong immune response against both influenza and Covid-19 in a Phase 1/2 clinical trial and has been deemed safe. The investigational vaccine, designed to provide dual protection against both flu and Covid-19 in a single shot, is now set to undergo Phase 3 trials among adults aged 50 and older later this year.
During the ongoing Phase 1/2 trial, the safety and immunogenicity of mRNA-1083 were compared to those of a standard flu shot in adults aged 50 to 64, as well as to the updated Covid-19 vaccine in adults aged 65 to 79. Moderna announced that the combination vaccine achieved similar or higher antibody titers compared to the licensed flu shot and the updated Covid-19 vaccine.
Notably, mRNA-1083 displayed a safety profile similar to the Covid-19 vaccine, with no new safety concerns identified. Moderna emphasized that while a two-in-one combination vaccine could be a valuable tool in combating respiratory illnesses, including flu and Covid-19, the mRNA-1083 vaccine will not be available for use during the current respiratory virus season.
Moderna expects potential regulatory approval for the combination vaccine by 2025 and views combination vaccines as an opportunity to enhance the consumer and provider experience while improving compliance with public health recommendations.
Other pharmaceutical companies, including Pfizer, BioNTech, and Novavax, have also been working on developing a combined flu and Covid-19 vaccine. These combination vaccines carry potential logistical benefits by reducing the number of required injections and minimizing storage challenges.
However, challenges exist in ensuring the compatibility and effectiveness of different vaccine components. The immune response may be compromised if the vaccines interfere with each other, while the safety factor must be considered as multiple vaccines may result in increased adverse reactions.
Additionally, a crucial aspect is whether enough people would be willing to take a combined flu and Covid-19 vaccine. The convenience of having a single vaccine for both diseases may help improve the uptake of vaccination among the population. Ultimately, the development of a successful and widely accepted combination vaccine could significantly alleviate the seasonal burden posed by these respiratory viruses on individuals, healthcare systems, and economies.